RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc. (RLMD) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.8) | C- (1.9) | C- (1.9) | C+ (2.6) | C- (2.1) |
| 2026-11-07 | C+ (2.5) | D+ (1.8) | C+ (2.5) | C- (1.9) | C+ (2.7) | C (2.3) |
| 2026-10-31 | C+ (2.5) | D+ (1.7) | C+ (2.5) | D+ (1.8) | C+ (2.7) | C (2.3) |
| 2026-10-24 | C+ (2.5) | D+ (1.7) | C+ (2.5) | C- (1.9) | C+ (2.6) | C (2.3) |
| 2026-10-17 | C+ (2.5) | D+ (1.7) | C+ (2.5) | C- (2.0) | C+ (2.6) | C (2.3) |